- The Delaware federal court ruling denies Pfizer, BioNTech, and Moderna their bids to exit Bayer's mRNA patent litigation at the pleading stage, so the case proceeds toward discovery.
- The decision extends legal overhang on the mRNA vaccine franchises of Pfizer, BioNTech, and Moderna, which face potential licensing costs or damages if Bayer prevails.
Quotes
“A federal judge in Delaware on Monday rejected Pfizer”